Chris Molloy, a non-executive director at RSA since 2009, joins RSA in a full-time capacity from IDBS, where he was VP, corporate development and marketing.
Molloy brings with him more than 20 years’ experience in life sciences, spanning the pharmaceuticals, biotechnology and start-up sectors.
He started out with Glaxo, where he held a range of management, research, business change and scientific collaboration roles through the company’s merger to become GlaxoSmithKline (GSK), before moving to Asia in 2004 as chief operating officer of emerging biotech firm MerLion Pharmaceuticals.
In addition to taking over as CEO at RSA, Molloy will retain his active scientific role in the pre-clinical development and licensing of new medicines for HIV with KFLP Biotech, a ‘virtual’ US R&D company.
“We are excited to have Chris on board as RSA’s CEO. He will continue to preserve the special culture and feel of RSA whilst making us even more professional as an executive search and interim business,” said executive chairman Nick Stephens.